ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares Purchased by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC raised its position in ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 16.9% in the 4th quarter, HoldingsChannel.com reports. The fund owned 301,419 shares of the company’s stock after acquiring an additional 43,640 shares during the quarter. Los Angeles Capital Management LLC’s holdings in ALX Oncology were worth $503,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Privium Fund Management B.V. boosted its stake in shares of ALX Oncology by 28.2% in the third quarter. Privium Fund Management B.V. now owns 509,059 shares of the company’s stock valued at $926,000 after purchasing an additional 112,093 shares during the period. XTX Topco Ltd acquired a new stake in ALX Oncology during the 3rd quarter worth approximately $578,000. Walleye Capital LLC boosted its position in ALX Oncology by 110.3% in the 3rd quarter. Walleye Capital LLC now owns 230,875 shares of the company’s stock valued at $420,000 after buying an additional 121,113 shares during the period. Wellington Management Group LLP grew its stake in shares of ALX Oncology by 15.2% in the third quarter. Wellington Management Group LLP now owns 167,831 shares of the company’s stock worth $305,000 after acquiring an additional 22,114 shares in the last quarter. Finally, Verition Fund Management LLC increased its position in shares of ALX Oncology by 308.4% during the third quarter. Verition Fund Management LLC now owns 133,025 shares of the company’s stock worth $242,000 after acquiring an additional 100,454 shares during the period. 97.97% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a report on Friday, January 24th. UBS Group decreased their price objective on ALX Oncology from $4.00 to $2.20 and set a “buy” rating for the company in a research note on Monday, January 27th. HC Wainwright cut their target price on shares of ALX Oncology from $25.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday, January 24th. Finally, Jefferies Financial Group cut shares of ALX Oncology from a “buy” rating to a “hold” rating and lowered their price target for the stock from $12.00 to $2.00 in a report on Thursday, December 19th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $3.05.

ALX Oncology Trading Down 6.4 %

NASDAQ:ALXO opened at $1.03 on Tuesday. The stock has a 50-day simple moving average of $1.44 and a 200-day simple moving average of $1.65. The stock has a market cap of $54.33 million, a P/E ratio of -0.35 and a beta of 0.96. ALX Oncology Holdings Inc. has a 1 year low of $0.96 and a 1 year high of $17.83. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82.

ALX Oncology Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.